If it does work, one wouldn't know by the CEO having to raise capital at a 8 penny conversion... 40 press releases touting B and nobody knows or cares outside IPIX's inner circle of a few... Even their only partner "Alphasigma" declined to get involved... Raising phase 3 funds will be exciting to see if data warrants. 1 billion shares outstanding we go...
Whatever the results, I expect Leo to present the facts and circumstances of the trial results accurately..any material misrepresentation will not end well...a failure or lackluster performance against Covid is no shame...misrepresenting that type of a result is a company killer...
failure against Covid doesn't mean B doesn't work for a multitude of other conditions...we have seen some decent evidence of that...it certainly has nothing to do with the development of Kevetrin
imo the difference between 3 days and 5 days is deminimus...well within the range of what's reasonable in determining efficacy...I am also wary of Russia for reasons that are obvious...its not a free country, period so there is ample reason to be circumspect about whatever they report...it better be corroborated by independent sources or its value is limited..especially as evidence to retail investors who will draw the obvious inferences
Phase I studies in most indications are in healthy volunteers (cancer being an exception).
By definition, therefore, it is not known if a product works until it is tested in Phase II.
Of course many products are shown not to work in Phase II, and there are countless examples of such products in COVID-19 that have been trotted out on this board under the general principle of the IPIX booster, that is, to quote Gore Vidal
"It is not enough to succeed. Others must fail."
There are even drugs that show great promise in Phase II but fail in the tougher arena of Phase III.
It's so easy for speculators with no understanding of biopharma to get hosed here in the Wild West of the OTC market.
I recommend talking to your relatives (son and daughter-in-law, if I recall correctly) who work in Drug Development, or reading an easy primer on Drug Development such as this:
"Phase 2
Study Participants: Up to several hundred people with the disease/condition.
Length of Study: Several months to 2 years
Purpose: Efficacy and side effects
Approximately 33% of drugs move to the next phase"
News 
Market Data 
Discover 
